- Home
- TNXP vs FRD Comparison
TNXP vs FRD Comparison
Compare TNXP & FRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- FRD
- Stock Information
- Founded
- TNXP 2007
- FRD 1965
- Country
- TNXP United States
- FRD United States
- Employees
- TNXP N/A
- FRD N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- FRD Steel/Iron Ore
- Sector
- TNXP Health Care
- FRD Industrials
- Exchange
- TNXP Nasdaq
- FRD Nasdaq
- Market Cap
- TNXP 197.9M
- FRD 159.1M
- IPO Year
- TNXP N/A
- FRD N/A
- Fundamental
- Price
- TNXP $15.12
- FRD $19.65
- Analyst Decision
- TNXP Buy
- FRD
- Analyst Count
- TNXP 1
- FRD 0
- Target Price
- TNXP $70.00
- FRD N/A
- AVG Volume (30 Days)
- TNXP 778.7K
- FRD 21.1K
- Earning Date
- TNXP 11-10-2025
- FRD 11-10-2025
- Dividend Yield
- TNXP N/A
- FRD 0.81%
- EPS Growth
- TNXP N/A
- FRD 43.48
- EPS
- TNXP N/A
- FRD 1.63
- Revenue
- TNXP $10,299,000.00
- FRD $510,450,000.00
- Revenue This Year
- TNXP $14.79
- FRD N/A
- Revenue Next Year
- TNXP $933.49
- FRD N/A
- P/E Ratio
- TNXP N/A
- FRD $12.10
- Revenue Growth
- TNXP N/A
- FRD 8.72
- 52 Week Low
- TNXP $6.76
- FRD $12.24
- 52 Week High
- TNXP $130.00
- FRD $23.50
- Technical
- Relative Strength Index (RSI)
- TNXP 35.51
- FRD 45.41
- Support Level
- TNXP $13.70
- FRD $19.14
- Resistance Level
- TNXP $18.25
- FRD $20.60
- Average True Range (ATR)
- TNXP 1.28
- FRD 1.27
- MACD
- TNXP 0.07
- FRD -0.21
- Stochastic Oscillator
- TNXP 26.08
- FRD 17.20
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.